IP Library Granted Patent US 8,153,725
Granted Patent B2
US 8,153,725 · App. 12/728,083 · Granted Apr 10, 2012

Supports for oligomer synthesis

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,153,725
App. No.
12/728,083
Granted
Apr 10, 2012
Kind
B2
Abstract

Universal linkers, their facile processes of manufacture and methods of using the same are provided.

Claims (46)

1. A compound having the formula:

wherein:

one of Q 1 and Q 2 is a protecting group, a phosphodiester linked nucleoside or a phosphodiester linked oligonucleotide and the other of Q 1 and Q 2 is a linkage attached to a support medium; and

A is a substituted or unsubstituted aromatic group.

2. The compound of claim 1 wherein A is an unsubstituted aromatic group.

3. The compound of claim 1 wherein A is phenyl.

4. The compound of claim 1 wherein said linkage attached to a support medium has the formula:

—C(═O)—(CH 2 ) n —C(═O)—

wherein n is from about 2 to about 8.

5. The compound of claim 4 wherein n is 2.

6. The compound of claim 1 wherein Q 1 is a protecting group.

7. The compound of claim 1 wherein Q 2 is a protecting group.

8. The compound of claim 1 wherein one of Q 1 and Q 2 is an acid labile hydroxyl protecting group.

9. The compound of claim 8 wherein said acid labile hydroxyl protecting group is 4-methoxytriphenylmethyl, 4,4′-dimethoxytriphenylmethyl, 9-phenylxanthenyl or substituted 9-phenylxanthenyl.

10. The compound of claim 9 wherein said acid labile hydroxyl protecting group is 4,4′-dimethoxytriphenylmethyl.

11. The compound of claim 1 wherein one of Q 1 and Q 2 is a phosphodiester linked nucleoside or oligonucleotide.

12. The compound of claim 1 wherein said support medium is controlled pore glass, oxalyl-controlled pore glass, silica-containing particles, polystyrene, copolymers of polystyrene and divinylbenzene, copolymers of dimethylacrylamide and N,N-bisacryloylethylenediamine, a soluble support medium or PEPS.

13. The compound of claim 12 wherein said support medium is controlled pore glass, polystyrene or copolymers of polystyrene.

14. The compound of claim 13 wherein said support medium is controlled pore glass.

15. The compound of claim 1 wherein said support medium is HL30 Primer solid support, OligoPrep solid support, Nittomar 200 solid support or Nittomar 250 solid support.

16. The compound of claim 1 having the formula:

wherein:

one of Q 1 and Q 2 is a protecting group, a phosphodiester linked nucleoside or a phosphodiester linked oligonucleotide and the other of Q 1 and Q 2 is a linkage attached to a support medium; and

A is a substituted or unsubstituted aromatic group.

17. The compound of claim 16 having the formula:

wherein:

SM is said support material;

A is a substituted or unsubstituted aromatic group; and

Pg is an acid labile hydroxyl protecting group.

18. The compound of claim 17 wherein:

A is unsubstituted aromatic group; and

Pg is 4,4′-dimethoxytriphenylmethyl.

19. The compound of claim 18 wherein A is phenyl.

20. The compound of claim 16 having the formula:

wherein:

SM is said support material;

A is a substituted or unsubstituted aromatic group; and

Pg is an acid labile hydroxyl protecting group.

21. The compound of claim 20 wherein:

A is unsubstituted aromatic group; and

Pg is 4,4′-dimethoxytriphenylmethyl.

22. The compound of claim 21 wherein A is phenyl.

23. A racemic mixture of compounds of the formula:

wherein:

for the first percentage of the mixture Q 3 is a protecting group and Q 4 is SM-C(═O)—(CH 2 ) 2 —C(═O)— and for the second percentage of the mixture Q 3 is SM-C(═O)—(CH 2 ) 2 —C(═O)— and Q 4 is a protecting group and wherein the combined first and second percentages equal essentially 100 percent of the mixture.

24. The mixture of claim 23 wherein said protecting group is dimethoxytrityl.

Assignments (1)
CHANGE OF NAME Recorded Jun 28, 2017
From: ISIS PHARMACEUTICALS, INC.
To: IONIS PHARMACEUTICALS, INC.
Reel/Frame 043029/0407 →